Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Afatinib Gliotrif 30 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
J0594 Busulfan Busulfex 1 mg Chemotherapy Alkylating Agent Alkylsulfonate No 1999 Jan 1, 2007 In Use
S0170 Anastrozole Arimidex 1mg Hormonal Therapy Aromatase Inhibitor Yes 1995 Jan 1, 2002 In Use
NA Axitinib Axitinib 5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct 1, 2016 In Use
J9043 Cabazitaxel Jevtana 1 mg Chemotherapy Antimitotic Agent Taxane No 2010 Jan 1, 2012 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
Q5101 Filgrastim Neupogen, Zarxio 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jul 1, 2015 In Use
Inavolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
J8522 Capecitabine Multiple 50mg Chemotherapy Antimetabolite Yes 2005 Sep 11, 2024 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 Jul 1, 2020 In Use
Q5113 Trastuzumab-pkrb Herzuma 10mg Immunotherapy Monoclonal Antibody HER2 No 2018 Jul 1, 2019 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan 1, 2017 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.